Treatment Tips : Med Marketplace - by Derek Thaczuk

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
POZ Focus

Back to home » HIV 101 » POZ Focus » Treatment Tips

Table of Contents



Med Marketplace

Comparison Shopping

 
What You're Talking About
It's Time for a TV Dramedy Series About Life With HIV (22 comments)

AHF Campaigns Against PrEP as a 'Public Health Intervention' (10 comments)

Partial Disclosure (blog) (8 comments)

True Story - An essay by a gay journalist and author who is tired of living in fear of HIV (8 comments)

Health Care is a Human Right (7 comments)

The WHO's Unwise Recommendation for Gay Men (blog) (7 comments)
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


emailprint

Med Marketplace

by Derek Thaczuk

Putting together an HIV drug regimen can be an overwhelming experience, especially for those who are newly diagnosed. Derek Thaczuk walks us through key factors to consider when shopping for the treatment combo that will work best for you.

Whether you’re starting HIV treatment for the first time or thinking of switching to new meds, there are a lot of factors to consider. For starters, there are more than two dozen drug options from which to choose. Other important considerations include: efficacy (what regimen is most likely to lower your viral load and
raise your CD4 cell count), drug resistance, dosing, interactions between antiretrovirals (ARVs) and other meds, and side effects.

Reginald Davis of Chicago knows firsthand just how overwhelming selecting an optimal drug combo can be. Soon after he tested positive for HIV in October 2006 at the age of 23, he discovered that his CD4 count was 150 cells, and he found himself under pressure to start ARV treatment ASAP. But before he started popping pills, Davis spent a month considering treatment options and talking about them with his health care provider. He also did lots of reading on his own. “Everyone comes into this, literally, ‘treatment-naive,’” he says. “You don’t know anything about all these treatments when you start.” His doc and health care team encouraged his learning—and his taking the lead in the decision making: “They said, ‘We’re the team looking after you, but the head of that team is you.’”

Given the wide array of effective ARVs now available, people living with HIV can expect their drug combo to meet their individual needs. Because HIV meds are most effective when taken correctly and consistently, finding a regimen that works well with your body and lifestyle is your best bet for optimal adherence and, subsequently, optimal health.

To help you make the best med choices, we’ll start, like Davis did, with the basics. For those taking ARVs for the first time, initial regimens typically draw from three classes: most commonly, two nucleoside reverse transcriptase inhibitors (NRTIs) combined with a powerful representative from either the non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) families.

Picking the most effective of these drugs is consideration No. 1. The U.S. Department of Health and Human Services’ (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents serves as the go-to source for this decision.

This regularly updated guide pools the latest drug data together, identifying “preferred” drugs based on the results of clinical trials and expert interpretation. All drugs recommended by the DHHS are tried and true in their ability to reduce viral loads and increase CD4 cells.

Two combos currently lead the Guidelines’ NRTI pack, and both are available in fixed-dose combinations that bundle two drugs into one pill: Truvada, containing Viread (tenofovir) and Emtriva (emtricitabine); and Epzicom, containing Ziagen (abacavir) and Epivir (lamivudine).

Of the NNRTIs, Sustiva (efavirenz) is the preferred DHHS option, except for women who are pregnant or trying to conceive, due to the risk for birth defects.
The three top-choice PIs are Kaletra (lopinavir), Lexiva (fosamprenavir) and Reyataz (atazanavir). These PIs usually get a boost from a dose of Norvir (ritonavir)—more on this below.

Even though the Guidelines narrow the list of treatment options down to the most potent drugs, there are still decisions to be made. This means individualizing treatment, based on each HIV-positive person’s specific needs and preferences. Claudia Martorell, MD, MPH, of Tufts University School of Medicine in Boston, says, “Everyone has different priorities. When you treat a patient, you have to know them well and talk about what those priorities are.”


Search: drug regimen, treatment combo


Scroll down to comment on this story.




Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[ Go to top ]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    mtaj0818
    Washington
    DC


    hollywoodvers1
    Los Angeles
    California


    jacob2608
    Panama City Beach
    Florida
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.